Elizabeth McKenna: An overview of the past 4 decades of development of ADC’s
Elizabeth McKenna, Executive Editor of Cancer Discovery at American Association for Cancer Research, shared on LinkedIn:
“Every now and then an opportunity comes along to publish a review article at exactly the right time by exactly the right authors – I’m very excited to share one such review article published online in Cancer Discovery today for the start of ENASymp24:
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development, by Raffaele Colombo, Paolo Tarantino, Jamie Rich, Patricia LoRusso, and Elisabeth (Liesbeth) de Vries
In this article, thought leaders in the field provide an overview of the past 4 decades of development of this drug class; discuss issues related to ADC toxicity, efficacy, stability, distribution, and disposition in normal tissues; and provide their perspective on challenges related to clinical optimization, sequencing strategies, and predictive biomarkers.”
Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute.
Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes.
She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023